ANG Lifesciences IPO is all about to make its debut on 29 Aug 2017 with issue size of INR 12.01 Cr
ANG Lifesciences India Limited was founded in 2006 and is a pharmaceutical firm that manufactures and sells finished pharmaceutical formulations in sterile dry powder injectable vials in India.
Sterile dry powder vials for antibiotics, ulcerative, glucocorticoids and anti-inflammatory drugs, antimalarials, and anesthetics are among the company’s goods. It produces goods in accordance with GMP specifications. However, the company aims to reach 90% or higher in the upcoming years despite operating at an average capacity utilization of 70% over the past two fiscal years. To increase its production capabilities, ANGL is probably also going to look into possible acquisitions. Wockhardt, DHS Maharashtra, Global Hospitals, Elder, Emcure, BPPI, the Government of Haryana, Hetero Healthcare, and other companies are among its clients.
INDUSTRY OVERVIEW
In terms of volume and value, the Indian pharmaceuticals market is the third largest worldwide. Branded generics make up the majority of the market, accounting for between 70 and 80 percent of the total. Twenty percent of the world’s generic medicine exports by volume come from India, which is the top generic drug supplier globally. The industry is very fragmented, and consolidation trends have just emerged. With a sizable pool of scientists and engineers, India has a considerable presence in the international pharmaceuticals industry. Indian pharmaceutical companies provide about 80% of the antiretroviral medications used to treat AIDS in the globe. Six Indian pharmaceutical firms have been granted licenses by the UN-backed Medicines Patent Pool to manufacture the generic form of the anti-AIDS drug tenofovir alafenamide for 112 developing nations.
ANG Lifesciences IPO Details
| IPO Date | Aug 29, 2017 to Aug 31, 2017 |
| Listing Date | Sep 8, 2017 |
| Face Value | ₹10 per share |
| Price | ₹80 per share |
| Lot Size | 1600 Shares |
| Total Issue Size | 1,500,800 shares(aggregating up to ₹12.01 Cr) |
| Issue Type | Fixed Price Issue IPO |
| Listing At | BSE SME |
Company Financials
| FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | ||
| Total revenue | 16.29 | 34.62 | 36.94 | 55.13 | 67.92 | |
| Total expenses | 16.14 | 34.17 | 36.33 | 52.91 | 64.11 | |
| Profit after tax | -0.06 | 0.19 | 0.40 | 1.65 | 2.92 |
Objects of the Issue
The object of the issue are:
1. To meet the working capital requirement;
2. To meet the expenses of the Issue.
ANG Lifesciences IPO Prospectus
Company Contact Information
ANG Lifesciences India Ltd
Darbara Complex SCO 113 I Flr,
Dist. Shopping Centre B Block,
Amritsar – 143001
Phone: +91-0183-5070118
Email: cs@anglifesciences.com
Website: http://www.anglifesciences.com
ANG Lifesciences IPO Registrar
Bigshare Services Pvt Ltd
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://www.bigshareonline.com/
ANG Lifesciences IPO Lead Manager(s)
- Guiness Corporate Advisors Pvt Ltd (Past IPO Performance)
Lead Manager Reports
- IPO Lead Manager Performance Summary
- IPO Lead Manager Performance Tracker
